Lung Cancer

First-Line Immunotherapy Continues to Best Chemo in Malignant Pleural Mesothelioma

By

Alan P. Lyss, MD

Publish Date October 29, 2021

Data suggest nivolumab plus ipilimumab provides a long-term survival benefit in patients with unresectable malignant pleural mesothelioma.

How COVID-19 Affected Management of Lung Nodule Programs

By

Rosemarie A. Tucci, MSN, RN, AOCN®

Publish Date September 13, 2021

Dramatic changes made to lung nodule programs due to COVID-19 included changes to screening criteria and follow-up protocols, plus a whole new group of patients.

Metformin Fails to Show Benefit in Non-Small Cell Lung Cancer Trials

By

Jon Kelvey

Publish Date August 12, 2021

Metformin did not improve progression-free or overall survival in either study.

Unmet Supportive Care Needs Impact QOL in Patients With Lung Cancer

Five studies showed a negative association between quality of life and unmet needs.

Mutations in STK11, KEAP1 Only Reduce Immunotherapy Efficacy in KRAS-Mutant Lung Cancer

STK11 and KEAP1 mutations were independent predictors of shorter progression-free and overall survival in KRAS-mutant cases.

EGFR Positivity May Be Poor Predictor of Recurrence in Non-Small Cell Lung Cancer

Despite high rates of recurrence, 37% of patients with stage IB-IIIA NSCLC remained disease-free at 5 years.

Proton Pump Inhibitors May Reduce Efficacy of Atezolizumab in Non-Small Cell Lung Cancer

Proton pump inhibitor use was tied to worse overall and progression-free survival.

Adjuvant Gefitinib No Better Than Chemo for NSCLC With EGFR Mutations

Gefitinib did not improve disease-free or overall survival.